| scholarly article | Q13442814 |
| P50 | author | Mark Olfson | Q91346889 |
| P2093 | author name string | Ramin Mojtabai | |
| Jonathan S. Comer | |||
| P2860 | cites work | Pharmacological treatment for psychotic depression | Q24245544 |
| National trends in the treatment of attention deficit hyperactivity disorder | Q28207694 | ||
| National trends in the outpatient diagnosis and treatment of bipolar disorder in youth | Q28244462 | ||
| A double-blind pilot study of risperidone in the treatment of conduct disorder | Q28376547 | ||
| Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment | Q32041795 | ||
| Comorbidity | Q33548186 | ||
| Trends in the prescribing of psychotropic medications to preschoolers | Q33891787 | ||
| Medication augmentation after the failure of SSRIs for depression. | Q33994373 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial | Q34341755 | ||
| A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents | Q34568810 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials | Q34619977 | ||
| Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002. | Q34734349 | ||
| National trends in psychotherapy by office-based psychiatrists | Q34804065 | ||
| Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety | Q34869621 | ||
| Psychotropic practice patterns for youth: a 10-year perspective | Q35040724 | ||
| Concomitant psychotropic medication for youths | Q35075423 | ||
| Outpatient treatment of child and adolescent depression in the United States | Q35603169 | ||
| Atypical antipsychotics in the treatment of children and adolescents: clinical applications. | Q35754262 | ||
| Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. | Q35956610 | ||
| The effect of atypical antipsychotic agents on prolactin levels in children and adolescents | Q36009440 | ||
| Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review | Q36009450 | ||
| A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder | Q36176008 | ||
| The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity. | Q36261143 | ||
| Psychotropic medication utilization in a child and adolescent mental health service | Q36503712 | ||
| Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder | Q37216281 | ||
| When is antipsychotic polypharmacy supported by research evidence? Implications for QI. | Q37306729 | ||
| Practice parameter on the use of psychotropic medication in children and adolescents | Q37582727 | ||
| Reduction of polypharmacy by feedback to clinicians | Q37709382 | ||
| Trends in mental health cost growth: an expanded role for management? | Q39982545 | ||
| Adjunctive antipsychotic treatment of adolescents with bipolar psychosis | Q40669405 | ||
| National trends in the use of psychotropic medications by children | Q43996317 | ||
| Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results | Q44051381 | ||
| Use of risperidone in a paediatric population: an observational study. | Q44581715 | ||
| Retrospective Study of Hepatic Enzyme Elevations in Children Treated With Olanzapine, Divalproex, and Their Combination | Q44618440 | ||
| A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial | Q44635621 | ||
| National Ambulatory Medical Care Survey: 2006 summary. | Q45267055 | ||
| A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents | Q46072648 | ||
| Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care | Q46184599 | ||
| Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study | Q46365535 | ||
| A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia | Q46395528 | ||
| Seizures induced by the combination treatment of methylphenidate and sertraline. | Q46517427 | ||
| Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin | Q46725722 | ||
| Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series | Q46725725 | ||
| Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization | Q46905721 | ||
| National Ambulatory Medical Care Survey: 1996 summary. | Q50643224 | ||
| The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. | Q50889035 | ||
| National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. | Q51801492 | ||
| Source-specific oppositional defiant disorder: comorbidity and risk factors in referred elementary schoolboys. | Q51908436 | ||
| Multiple psychotropic medication use for youths: a two-state comparison. | Q51932599 | ||
| Concomitant pharmacotherapy among youths treated in routine psychiatric practice. | Q51932601 | ||
| Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. | Q52004293 | ||
| The effects of methylphenidate and lithium on attention and activity level | Q55039911 | ||
| Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 2002 | Q55953463 | ||
| Risperidone and tardive dyskinesia | Q71819037 | ||
| Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 | ||
| Polypharmacy: when is it rational? | Q80112030 | ||
| National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge | Q80868865 | ||
| Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study | Q83294329 | ||
| Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports | Q83865677 | ||
| Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome | Q83974170 | ||
| Practice guideline for the treatment of patients with bipolar disorder (revision) | Q95789383 | ||
| Psychotropic medication use in children and adolescents: a study from France | Q95797847 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | teenager | Q1492760 |
| P304 | page(s) | 1001-1010 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of the American Academy of Child and Adolescent Psychiatry | Q6296081 |
| P1476 | title | National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007 | |
| National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 | |||
| P478 | volume | 49 |
| Q37719385 | 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment |
| Q33820624 | A novel group therapy for children with ADHD and severe mood dysregulation. |
| Q35305166 | A prospective study of adolescents' nonmedical use of anxiolytic and sleep medication |
| Q35011070 | A retrospective study of antipsychotic drug switching in a pediatric population |
| Q34341232 | Adverse effects of psychotropic medications in children: predictive factors |
| Q36117558 | Age and Cohort Patterns of Medical and Nonmedical Use of Controlled Medication Among Adolescents |
| Q37324915 | American parents' willingness to prescribe psychoactive drugs to children: a test of cultural mediators. |
| Q28287983 | Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability |
| Q37852719 | Antipsychotic drug toxicology in children |
| Q34194447 | Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization |
| Q47308229 | Capitalizing on Scientific Advances to Improve Access to and Quality of Children's Mental Health Care |
| Q40400512 | Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. |
| Q47416741 | Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. |
| Q48404311 | Clinical characteristics and outpatient mental health service use of transition-age youth in the USA. |
| Q38113748 | Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs |
| Q50090404 | Community Mental Health Providers' Beliefs About Addressing Weight Loss Among Youth Clients with Serious Emotional Disturbance and Overweight/Obesity: An Elicitation Study. |
| Q61806933 | Comorbidity of developmental trauma disorder (DTD) and post-traumatic stress disorder: findings from the DTD field trial |
| Q38086176 | Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events |
| Q36373562 | Correlates of weight gain during long-term risperidone treatment in children and adolescents |
| Q60049284 | Defining pediatric polypharmacy: A scoping review |
| Q39486862 | Development of a refill pattern method to measure polypharmacy in administrative claims databases |
| Q39250517 | Diagnosis in young children: how a father's perceptions of mental health change |
| Q37635320 | Diagnostic profiles and predictors of treatment outcome among children and adolescents attending a national psychiatric hospital in Botswana |
| Q29353662 | Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands |
| Q40007874 | Does Patient Race/Ethnicity Influence Physician Decision-Making for Diagnosis and Treatment of Childhood Disruptive Behavior Problems? |
| Q47309783 | Does misuse lead to a disorder? The misuse of prescription tranquilizer and sedative medications and subsequent substance use disorders in a U.S. longitudinal sample |
| Q48372273 | Effect of age on the profile of psychotropic users: results from the 2010 National Ambulatory Medical Care Survey |
| Q35395815 | Evidence-based psychological treatments for mental disorders: modifiable barriers to access and possible solutions |
| Q38818252 | Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD. |
| Q38920204 | Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment |
| Q38727636 | Fostering Psychotropic Medication Oversight for Children in Foster Care: A National Examination of States' Monitoring Mechanisms. |
| Q34615950 | Inattention symptoms and the diagnosis of comorbid attention-deficit/hyperactivity disorder among youth with generalized anxiety disorder |
| Q34723474 | Internet-delivered, family-based treatment for early-onset OCD: a preliminary case series |
| Q36720726 | Iron deficiency in pediatric patients in long-term risperidone treatment |
| Q35622010 | Length of stay of pediatric mental health emergency department visits in the United States |
| Q33836810 | Long-term trend in pediatric antidepressant use, 1983-2007: a population-based study |
| Q35875587 | Mental Health Care Delivered to Younger and Older Adults by Office-Based Physicians Nationally |
| Q37947095 | Metabolic and cardiovascular adverse effects associated with antipsychotic drugs |
| Q36271087 | Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study |
| Q35667230 | Pediatric Bipolar Disorder: Subtype Trend and Impact of Behavioral Comorbidities |
| Q90569369 | Pharmacotherapy Adherence for Pediatric Anxiety Disorders: Predictors and Relation to Child Outcomes |
| Q35762240 | Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up. |
| Q35544742 | Point-of-Care Child Psychiatry Expertise: The Massachusetts Child Psychiatry Access Project. |
| Q33655284 | Polypharmacy among children and adolescents with psychiatric disorders in a mental referral hospital in Botswana |
| Q60438395 | Polypharmacy in Attention Deficit Hyperactivity Disorder Treatment: Current Status, Challenges and Next Steps |
| Q36841579 | Polypharmacy in psychiatry: a review |
| Q38214474 | Polypharmacy in the treatment of subjects with intellectual disability |
| Q38063355 | Polypharmacy with antidepressants in children and adolescents |
| Q37247927 | Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents |
| Q39096696 | Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists. |
| Q38195068 | Prescribing for depressed adolescents: office decision-making in the face of limited research evidence |
| Q33617631 | Prescribing pattern of psychotropic medications in child psychiatric practice in a mental referral hospital in Botswana |
| Q90414107 | Prescribing patterns of polypharmacy in Korean pediatric patients |
| Q41649070 | Prescription Pattern of Antidepressants for Children and Adolescents in Korea Based on Nationwide Data |
| Q37688553 | Prescription of psychiatric medications and polypharmacy in the LAMS cohort |
| Q44758533 | Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study |
| Q34063651 | Psychotropic medication characteristics for special education students with emotional and/or behavioral disorders |
| Q37567443 | Psychotropic medication monitoring checklists: use and utility for children in residential care |
| Q37268793 | Psychotropic medication use and polypharmacy in children with autism spectrum disorders |
| Q90030941 | Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders |
| Q34486230 | Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial |
| Q27324418 | Rationale and Considerations for the Internet-Based Delivery of Parent-Child Interaction Therapy |
| Q39652199 | Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory |
| Q34094034 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression |
| Q36949869 | Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. |
| Q37667578 | Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents |
| Q89483192 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization |
| Q34552192 | Stimulant and atypical antipsychotic medications for children placed in foster homes |
| Q36543244 | Stimulant medication use in children: a 12-year perspective |
| Q41323022 | Ten-Year Trends In Treatment Services For Children With Attention Deficit Hyperactivity Disorder Enrolled In Medicaid |
| Q36707994 | The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School |
| Q57151377 | The Impact of Psychotropic Medications on Bone Health in Youth |
| Q36677600 | The diminished pipeline for medications to treat mental health and substance use disorders |
| Q34660624 | The occasional case against broad dissemination and implementation: retaining a role for specialty care in the delivery of psychological treatments |
| Q38120236 | The prevalence of at-risk development in children 30 to 60 months old presenting with disruptive behaviors |
| Q36454422 | The role of parent characteristics in community-based medication treatment for children with disruptive behavior problems |
| Q35595839 | The treatment of severe child aggression (TOSCA) study: Design challenges |
| Q38180865 | The use of antipsychotics in preschoolers: a veto or a sensible last option? |
| Q38027452 | The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective |
| Q52816425 | Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications. |
| Q46588602 | Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. |
| Q36423616 | Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010 |
| Q35962531 | Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008 |
| Q44842205 | Trends in psychotropic use in Saskatchewan from 1983 to 2007. |
| Q28304087 | Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011 |
| Q46814329 | Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. |
| Q33699936 | Use of Psychotropic Medications among Youth in Treatment Foster Care |
| Q38184948 | Use of SSRIs among Danish children: a nationwide study |
| Q37699333 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? |
| Q26774758 | Why the Diagnosis of Attention Deficit Hyperactivity Disorder Matters |
| Q93028702 | [Polypharmacy of psychotropic drugs in child and adolescent psychiatry in Germany - rather the rule than the exception] |
| Q88597090 | [Validation of interaction databases in psychopharmacotherapy] |
Search more.